Anadrol and HMG Interaction: Synergistic | Peptide Database

Join others researching PP405 — share findings, ask questions, and learn from real experiences PP405 is an investigational topical drug developed by Pelage Pharmaceuticals for the treatment of androgenetic alopecia. Based on research conducted at UCLA, PP405 works through a fundamentally different mechanism than existing hair loss treatments: rather than blocking androgens like finasteride or promoting blood flow like minoxidil, it targets the metabolic dormancy of hair follicle stem cells directly. By inhibiting the mitochondrial pyruvate carrier (MPC1/MPC2), PP405 causes pyruvate accumulation in hair follicle stem cells, stimulating lactate dehydrogenase activity and triggering a metabolic shift that reactivates dormant follicles. Phase 2a clinical trial results showed increased hair count and thickness with a 0.05% gel formulation applied once daily. As of 2025, the drug has completed Phase 2a trials, with Phase 3 trials planned for 2026. PP405 is a dual inhibitor of the mitochondrial pyruvate carrier complex, targeting both the MPC1 and MPC2 subunits. Under normal conditions, the MPC transports pyruvate from the cytoplasm into the mitochondrial matrix, where it enters the tricarboxylic acid (TCA) cycle for oxidative metabolism. In hair follicle stem cells (HFSCs), this standard metabolic pathway is associated with quiescence and dormancy. By blocking MPC1/MPC2, PP405 prevents pyruvate from entering the mitochondria, causing it to accumulate in the cytoplasm. This pyruvate buildup stimulates lactate dehydrogenase (LDH) activity, which converts pyruvate to lactate, shifting the cell's metabolic profile toward aerobic glycolysis. This metabolic reprogramming mimics the signaling environment that naturally triggers HFSCs to exit quiescence and re-enter the cell cycle. The activated stem cells then initiate a new anagen (growth) phase in dormant hair follicles. Critically, this mechanism is entirely independent of the androgen/DHT pathway targeted by finasteride and dutasteride, and distinct from the vasodilatory effects of minoxidil, meaning PP405 could be effective regardless of a patient's androgen status.

Nandrolone (Deca-Durabolin and NPP) elevates prolactin through progestogenic activity. Cabergoline is considered the gold standard for preventing and treating prolactin-related side effects during nandrolone cycles, including sexual dysfunction and progesterone-mediated gynecomastia. Trenbolone is a potent progestin that can significantly elevate prolactin in some users. Cabergoline controls prolactin-driven side effects such as lactation, nipple sensitivity, erectile dysfunction, and anorgasmia that may occur during trenbolone cycles. Elevated prolactin from 19-nor compounds commonly causes decreased libido, erectile dysfunction, and difficulty reaching orgasm (often called 'deca dick'). Cabergoline restores normal sexual function by normalizing prolactin levels. FDA-approved for the treatment of hyperprolactinemic disorders of various etiologies, including idiopathic hyperprolactinemia and prolactin-secreting pituitary adenomas (micro- and macroadenomas). Normalizes prolactin in over 85% of patients. First-line medical therapy for prolactin-secreting pituitary tumors. Cabergoline achieves significant tumor size reduction in the majority of patients, often avoiding the need for surgical intervention.